Bruker (NASDAQ:BRKR) Releases FY 2026 Earnings Guidance

Bruker (NASDAQ:BRKR) updated its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.100-2.150 for the period, compared to the consensus estimate of 2.120. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Guggenheim boosted their price target on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Barclays increased their price target on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Citigroup raised their price objective on shares of Bruker from $44.00 to $60.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Finally, TD Cowen reiterated a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Bruker presently has an average rating of “Hold” and an average target price of $57.14.

Bruker Trading Up 2.1%

Shares of NASDAQ:BRKR traded up $1.05 during midday trading on Wednesday, hitting $51.35. 1,001,613 shares of the stock were exchanged, compared to its average volume of 2,403,708. The business’s 50-day moving average price is $58.59 and its 200 day moving average price is $46.71. The stock has a market capitalization of $7.82 billion, a price-to-earnings ratio of -213.96, a P/E/G ratio of 2.06 and a beta of 1.28. Bruker has a 12 month low of $28.53 and a 12 month high of $65.30. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The company had revenue of $838.50 million during the quarter, compared to analysts’ expectations of $853.57 million. During the same quarter in the prior year, the firm posted $0.32 earnings per share. The business’s quarterly revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts predict that Bruker will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were given a dividend of $0.05 per share. The ex-dividend date was Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio is presently -83.33%.

More Bruker News

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported adjusted earnings of $0.49 per share, above the $0.38 analyst consensus and up from $0.32 a year earlier. Revenue increased 5.2% year over year to $838.5 million. Bruker Q2 Earnings Beat Estimates
• Positive Sentiment: Management highlighted margin strength on the earnings call, while maintaining fiscal 2026 adjusted EPS guidance of $2.10 to $2.15, broadly consistent with the $2.12 analyst expectation. Bruker Earnings Call Highlights Margin Strength
• Neutral Sentiment: The company maintained its expectation for continued organic growth, but lowered reported full-year revenue guidance to approximately $3.54 billion to $3.57 billion from $3.57 billion to $3.60 billion. Bruker attributed the adjustment primarily to foreign-exchange and tax assumptions rather than weaker underlying organic growth. Bruker Revenue Outlook and Q3 Timing Shift
• Negative Sentiment: Quarterly revenue fell short of the roughly $853.6 million consensus estimate. Investors also reacted to management’s expectation that about $20 million of semiconductor-related revenue will shift from the third quarter into the fourth quarter, creating a weaker near-term revenue profile.
• Negative Sentiment: Bruker recorded a $134.9 million non-cash goodwill impairment tied to its automation and spatial biology businesses, resulting in a GAAP diluted loss of $0.41 per share. Soft U.S. academic demand and a low-double-digit percentage decline in Asia-Pacific revenue added to concerns about operating momentum. Bruker Q2 Earnings Snapshot

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BRKR. Pacer Advisors Inc. increased its position in shares of Bruker by 42.8% in the fourth quarter. Pacer Advisors Inc. now owns 20,822 shares of the medical research company’s stock valued at $981,000 after acquiring an additional 6,242 shares during the period. Alberta Investment Management Corp purchased a new stake in shares of Bruker in the 4th quarter worth approximately $1,748,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Bruker during the fourth quarter valued at approximately $266,000. Utah Retirement Systems purchased a new position in Bruker during the fourth quarter valued at approximately $257,000. Finally, Wellington Management Group LLP purchased a new position in Bruker during the fourth quarter valued at approximately $8,172,000. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.